Long Considerations for $IFRX

17 jun 2019

>Bio of InflaRX<
2008 - Dutch pharma company founded in Germany
2017 - IPO on NASDAQ with gross proceeds of +100M
2018 - Second round of funding with +100M
2019 - Balance sheet shows working capital > 150M

>My opinion<
Seems like this company has recently hit a rough patch as far as their scientific studies go, but the financials look rock solid.
I don't think there will be another opportunity in the future to buy in at ~$3. I entered at $3.20 and placed a stop loss at $2.95 for safety.
I think IFRX could be a potential 10 bagger (10x returns), especially looking at the weekly chart and seeing the share value increased to $30 after IPO in just 14 weeks.
My estimate for value to return to double digits is 2-3 weeks time, since InflaRX released a statement on June 13, 2019 that their first patient is being treated.
These initial trials tend to run multiple months, with weekly reports generated (though they may be published with delay)
I expect InflaRX to publish results as they are produced to help out their shareholders.

>Notes<
Multiple medical studies in the USA and EU.
Estimated # of patients that may benefit from medicine is > 500,000.
Active press releases here > inflarx.de/Home/Investors/Press-Releases.html
Financials published here > inflarx.de/Home/Investors/Financial-Information.html